New York Eye and Ear Infirmary
Adjust: Text Size Make Font Smaller Make Font Larger Print this Page: Normal Print Friendly Large Print Friendly Accessibility Info

Wet AMD Eyedrop Treatment Trial

Study Title

A Phase 2b dose-evaluation Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration

Enrollment Status

This study is currently recruiting participants.

Purpose

The purpose of this study is to evaluate how tolerable, safe, and effective it is to give Pazopanib eye drops to adults with Wet AMD compared to Ranibizumab injections.

Eligibility

Ages Eligible for Study: 50 years old and older

Genders Eligible for Study: Both

Inclusion Criteria

  • Subject has the diagnosis of ACTIVE Wet (Exudative) AMD.
  • Must have had at least three prior injections of Lucentis, Macugen or Avastin for treatment for the Wet AMD.
  • Aged 50 to 75 years.
  • Relatively good general medical health.

Contact Information

Dr. Richard Rosen, Retina Vitreous Specialist
Katy Tai, Research Manager
ktai@nyee.edu or 212-979-4251

 

Home > Current Research > Clinical Trials in Ophthalmology > Wet AMD Eyedrop Treatment Trial